Publication details

High-Risk Multiple Myeloma: Different Definitions, Different Outcomes?

Authors

PASZEKOVÁ Helena KRYUKOV Fedor KUBICZKOVÁ Lenka HÁJEK Roman ŠEVČÍKOVÁ Sabina

Year of publication 2014
Type Article in Periodical
Magazine / Source Clinical lymphoma, myeloma & leukemia
MU Faculty or unit

Faculty of Medicine

Citation
Doi http://dx.doi.org/10.1016/j.clml.2013.09.004
Field Oncology and hematology
Keywords Cytogenetics; GEP; High-risk disease; MGUS; Multiple myeloma; Prognosis
Description Multiple myeloma (MM) is a clonal plasma cell malignancy. Although MM is still not completely curable, it can be maintained at the level of a long-term chronic condition. Irrespective of the treatment strategy, relapse is still a major problem for most patients. Approximately 10% to 15% of all MM patients relapse early and have poor prognosis and outcome. Currently, there are many ways of identifying these high-risk patients using cytogenetics or molecular biology. Despite these various approaches to definition of high risk patients, a clear definition of high-risk MM has not been widely accepted. In this review, we discuss and compare various approaches, and their strengths and weaknesses in early identification of high-risk MM patients.
Related projects:

You are running an old browser version. We recommend updating your browser to its latest version.

More info